Simple item page
 

Antiviral effect of poly(styrene 4-sulfonate) (PSSNa) on feline calicivirus oral infections in cats—field study

cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid0000-0003-1630-2938
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid527456dc-1715-40e8-bbcd-4761fce356aa
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
dc.abstract.enFeline calicivirus (FCV) infection causes nasal discharge, oral mucosa inflammation, ulcerations, gingivitis, and conjunctivitis, often progressing to chronic gingivostomatitis, severe pneumonia, and fatal systemic infections. With no antivirals currently available, poly(sodium 4-styrene sulfonate) (PSSNa) was identified in 2019 as a safe inhibitor in vitro. In this preliminary single-center, randomized, double-blind, placebo-controlled field study, we further characterized the PSSNa’s safety profile and tested its efficacy in cats after topical oral application. Twenty-eight cats were enrolled in the study, and they were initially treated with standard dental therapy, followed by adjuvant local oral application of PSSNa or placebo. After 4 weeks, PSSNa demonstrated a favorable safety profile with no adverse effects. The treatment group showed a significant decrease in viral load (p = 0.001) compared to placebo (p = 0.012). Disease symptoms improved significantly, though the oral health index remained unchanged. Additionally, PSSNa showed activity against multiple genetically diverse isolates, indicating a potential, exploratory link between genetic background and treatment outcome. Summarizing, this study presents initial data on the efficacy and tolerability of PSSNa treatment for FCV infections in cats. Nevertheless, several significant limitations should be acknowledged, including inconsistent drug administration by owners, non-sterile housing, sample size, variable oral disease severity, and concurrent treatments.
dc.affiliationWydział Medycyny Weterynaryjnej i Nauk o Zwierzętach
dc.affiliation.instituteKatedra Nauk Przedklinicznych i Chorób Zakaźnych
dc.contributor.authorSynowiec, Aleksandra
dc.contributor.authorPachota, Magdalena
dc.contributor.authorKrejmer-Rabalska, Martyna
dc.contributor.authorZiemann, Daria
dc.contributor.authorSzczubiałka, Krzysztof
dc.contributor.authorJank, Michał
dc.contributor.authorRabalski, Lukasz
dc.contributor.authorNowakowska, Maria
dc.contributor.authorGawor, Jerzy P.
dc.contributor.authorPyrć, Krzysztof
dc.date.access2026-01-20
dc.date.accessioned2026-01-20T10:13:30Z
dc.date.available2026-01-20T10:13:30Z
dc.date.copyright2026-01-19
dc.date.issued2026
dc.description.accesstimeat_publication
dc.description.bibliographyil., bibliogr.
dc.description.financepublication_nocost
dc.description.financecost0,00
dc.description.if5,2
dc.description.number1
dc.description.points70
dc.description.versionfinal_published
dc.description.volume46
dc.identifier.doi10.1080/01652176.2026.2616395
dc.identifier.eissn1875-5941
dc.identifier.issn0165-2176
dc.identifier.urihttps://sciencerep.up.poznan.pl/handle/item/7036
dc.identifier.weblinkhttps://www.tandfonline.com/doi/full/10.1080/01652176.2026.2616395
dc.languageen
dc.pbn.affiliationveterinary science
dc.relation.ispartofVeterinary Quarterly
dc.relation.pagesart. 2616395
dc.rightsCC-BY
dc.sciencecloudnosend
dc.share.typeOPEN_JOURNAL
dc.subject.enFeline calicivirus (FCV)
dc.subject.enpoly(sodium 4-styrenesulfonate)
dc.subject.enPSSNa
dc.subject.enfieldstudies
dc.subject.enantivirals
dc.titleAntiviral effect of poly(styrene 4-sulfonate) (PSSNa) on feline calicivirus oral infections in cats—field study
dc.typeJournalArticle
dspace.entity.typePublication
oaire.citation.issue1
oaire.citation.volume46